832 related articles for article (PubMed ID: 23135914)
1. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.
Badoual C; Hans S; Merillon N; Van Ryswick C; Ravel P; Benhamouda N; Levionnois E; Nizard M; Si-Mohamed A; Besnier N; Gey A; Rotem-Yehudar R; Pere H; Tran T; Guerin CL; Chauvat A; Dransart E; Alanio C; Albert S; Barry B; Sandoval F; Quintin-Colonna F; Bruneval P; Fridman WH; Lemoine FM; Oudard S; Johannes L; Olive D; Brasnu D; Tartour E
Cancer Res; 2013 Jan; 73(1):128-38. PubMed ID: 23135914
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers.
Badoual C; Hans S; Rodriguez J; Peyrard S; Klein C; Agueznay Nel H; Mosseri V; Laccourreye O; Bruneval P; Fridman WH; Brasnu DF; Tartour E
Clin Cancer Res; 2006 Jan; 12(2):465-72. PubMed ID: 16428488
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
4. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
5. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
Spanos WC; Nowicki P; Lee DW; Hoover A; Hostager B; Gupta A; Anderson ME; Lee JH
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1137-46. PubMed ID: 19917928
[TBL] [Abstract][Full Text] [Related]
6. PD-1 Status in CD8
Kansy BA; Concha-Benavente F; Srivastava RM; Jie HB; Shayan G; Lei Y; Moskovitz J; Moy J; Li J; Brandau S; Lang S; Schmitt NC; Freeman GJ; Gooding WE; Clump DA; Ferris RL
Cancer Res; 2017 Nov; 77(22):6353-6364. PubMed ID: 28904066
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.
Kim HR; Ha SJ; Hong MH; Heo SJ; Koh YW; Choi EC; Kim EK; Pyo KH; Jung I; Seo D; Choi J; Cho BC; Yoon SO
Sci Rep; 2016 Nov; 6():36956. PubMed ID: 27841362
[TBL] [Abstract][Full Text] [Related]
8. Functional HPV-specific PD-1
Eberhardt CS; Kissick HT; Patel MR; Cardenas MA; Prokhnevska N; Obeng RC; Nasti TH; Griffith CC; Im SJ; Wang X; Shin DM; Carrington M; Chen ZG; Sidney J; Sette A; Saba NF; Wieland A; Ahmed R
Nature; 2021 Sep; 597(7875):279-284. PubMed ID: 34471285
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
10. Spatial Profiles of Intratumoral PD-1
Yoshimura K; Tsujikawa T; Mitsuda J; Ogi H; Saburi S; Ohmura G; Arai A; Shibata S; Thibault G; Chang YH; Clayburgh DR; Yasukawa S; Miyagawa-Hayashino A; Konishi E; Itoh K; Coussens LM; Hirano S
Front Immunol; 2021; 12():769534. PubMed ID: 34777389
[TBL] [Abstract][Full Text] [Related]
11. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
[TBL] [Abstract][Full Text] [Related]
13. Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors.
van Kempen PM; Noorlag R; Swartz JE; Bovenschen N; Braunius WW; Vermeulen JF; Van Cann EM; Grolman W; Willems SM
Cancer Immunol Immunother; 2016 May; 65(5):575-85. PubMed ID: 26993499
[TBL] [Abstract][Full Text] [Related]
14. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
[TBL] [Abstract][Full Text] [Related]
15. Peritumoral cuffing by T-cell tumor-infiltrating lymphocytes distinguishes HPV-related oropharyngeal squamous cell carcinoma from oral cavity squamous cell carcinoma.
Poropatich K; Hernandez D; Fontanarosa J; Brown K; Woloschak G; Paintal A; Raparia K; Samant S
J Oral Pathol Med; 2017 Nov; 46(10):972-978. PubMed ID: 28632936
[TBL] [Abstract][Full Text] [Related]
16. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.
Karim R; Jordanova ES; Piersma SJ; Kenter GG; Chen L; Boer JM; Melief CJ; van der Burg SH
Clin Cancer Res; 2009 Oct; 15(20):6341-7. PubMed ID: 19825956
[TBL] [Abstract][Full Text] [Related]
17. [Current events in immunotherapy for upper aerodigestive tract cancer].
Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model.
Ishida E; Lee J; Campbell JS; Chakravarty PD; Katori Y; Ogawa T; Johnson L; Mukhopadhyay A; Faquin WC; Lin DT; Wirth LJ; Pierce RH; Pai SI
Cancer Immunol Immunother; 2019 Aug; 68(8):1273-1286. PubMed ID: 31243491
[TBL] [Abstract][Full Text] [Related]
19. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors.
Wood O; Woo J; Seumois G; Savelyeva N; McCann KJ; Singh D; Jones T; Peel L; Breen MS; Ward M; Garrido Martin E; Sanchez-Elsner T; Thomas G; Vijayanand P; Woelk CH; King E; Ottensmeier C;
Oncotarget; 2016 Aug; 7(35):56781-56797. PubMed ID: 27462861
[TBL] [Abstract][Full Text] [Related]
20. Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC.
Williams R; Lee DW; Elzey BD; Anderson ME; Hostager BS; Lee JH
Head Neck; 2009 Jul; 31(7):911-8. PubMed ID: 19283850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
